Rosen Comments on Korean Pharma Companies Doing Business in the U.S.

18 April 2019 Korea Biomedical Review News
Partner David Rosen was quoted in a Korea Biomedical Review article, "How Korean pharma companies can succeed in US," about how Korean pharmaceutical and biosimilar companies can find success in America.

Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.

"Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product," he said. "Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them."

Related Services


RCE PTA Carve-Out Resumes After Interference
18 September 2019
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.